focus -WSS

focus

author：explore 2025-09-06 02:04:06 - browse：81

Exact Sciences headquarters. -- biotech coverage from STAT — Exact Sciences' headquarters in Madison, Wis. Wikimedia Commons

Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue.

That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading on Wednesday, shortly after Exact released its financial updates, shares tumbled as low as $47.24.

The seemingly paradoxical result reflects worries about a potential slowdown in future growth at Exact, a $10 billion biotech best known for Cologuard, a colon cancer screening test that detects blood and DNA from stool samples. The test, which first won regulatory approval in 2014, was designed to boost cancer screening rates by providing a more convenient alternative to colonoscopies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

WSS

Researchers tackle phage therapy hurdles for wider adoption

Medicare Advantage enrollment hits roughly 33.4 million

Medicare proceeds with plan to claw back hospital funds

Elevance, SCAN deals highlight health insurer acquisition scrutiny

FDA warns medical device makers about rise in fabricated data

Humans aren't the only ones with an imagination. Rats have it too

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

ChatGPT in medicine: STAT answers readers' burning questions

All of Us, NIH's precision medicine initiative, gets a big boost

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare Advantage enrollment hits roughly 33.4 million

What does generative AI mean for health care? We asked experts

Explaining an after

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

MD Anderson's Padmanee Sharma responds to research credit suit

focus

Flagship Pioneering startup Sonata Therapeutics lays off 21

How neuroscience research could help beat back brain cancer

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Ukraine seeks to reclaim its role as a hub for clinical trials

In 'major milestone,' FDA approves first cell therapy for solid tumors

hotspot

focus

focus

focus